Wilson Bellanon cleavable linkerWith state-of-art equipment, advanced techniques, and well-established “DrugLnk” organic synthesis platform, scientists from Creative…Oct 20, 2023Oct 20, 2023
Wilson BellaNon-compartmental ModelingNon-compartmental model thinks of an organism as only one homogenous compartment. It presumes that a drug’s blood-plasma concentration is a…Oct 20, 2023Oct 20, 2023
Wilson Bellablood monkeybout the African Green Monkey: African Green Monkey has long been one of the most important non-human primate models for biomedical…Oct 20, 2023Oct 20, 2023
Wilson BellaAnti-RSV Recombinant Antibody (Palivizumab) (CAT#: TAB-009)Recombinant monoclonal antibody to Human RSV. Palivizumab is a monoclonal antibody produced by recombinant DNA technology. It is used in…Oct 20, 2023Oct 20, 2023
Wilson BellaHuman Macrophage CultureMacrophages are able to initiate a particular type of inflammatory response via the release of a certain pattern of cytokines. They play a…Oct 17, 2023Oct 17, 2023
Wilson BellaCompound-specific SAs HaptensCreative Biolabs has extensive experience and impressive performance in the field of small molecule drugs and antibody development. With…Oct 17, 2023Oct 17, 2023
Wilson BellaAI Model Training DataThe novel AI-aided drug discovery strategies have aroused great attention in clinical settings. To meet the challenging requirements…Oct 17, 2023Oct 17, 2023
Wilson BellaMicrobial FermentationLive biotherapeutic products (LBPs) are defined as live organisms (bacteria or yeast) designed and developed to treat, cure, or prevent…Oct 17, 2023Oct 17, 2023
Wilson BellaCREATIVE BIOLABS LAUNCHES PRECIAB™ PLATFORM SPECIALIZED IN ANTIBODY ENGINEERINGCreative Biolabs has over 10 years of experience in computational structural biology and antibody engineering that has developed a…Jan 3, 2021Jan 3, 2021
Wilson BellaJOINTLY DISCOVER OPTIMAL PROTAC MOLECULES WITH CREATIVE BIOLABSThe achievement by far of PROTAC based drugs can never be separated from the discovery of how cells clean up abnormal proteins, i.e., the…Jan 3, 2021Jan 3, 2021